Key outcomes from fda type a meeting and mesoblast next steps to achieve ryoncil approval

New york, sept. 21, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-l in the treatment of pediatric and adult steroid-refractory acute graft versus host disease (sr-agvhd), following a type a meeting held with the united states food and drug administration (fda). fda clarified that the key remaining issue for pediatric approval is providing further evidence that the potency assay will assure the consistent efficacy of commercial product.
MESO Ratings Summary
MESO Quant Ranking